GlassScriptPhysician profile
Mark R Homicz
NPI 1336198449
$2,000.90
in general payments reported to CMS, 2019-2025
13 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $95.89 · 2021: $400 · 2022: $363 · 2023: $365 · 2024: $210 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $392.46 | 2021-2025 | Nucala |
| Alk-Abello, INC | $276.04 | 2021-2023 | Odactra, Grastek |
| Regeneron Healthcare Solutions, INC. | $237.93 | 2021-2025 | Dupixent |
| Genzyme Corporation | $221.55 | 2019-2025 | |
| Optinose US, INC. | $181.52 | 2019-2024 | |
| Intersect Ent, INC. | $154.47 | 2019-2022 | |
| Medtronic, INC. | $137.14 | 2023 | Pteye Parathyroid Detection System, Sonicision |
| Aerin Medical INC. | $109.13 | 2019-2022 | |
| Ethicon US, LLC | $88.87 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $81.34 | 2021-2023 | |
| Smith+Nephew, INC. | $77.71 | 2021-2025 | Tula, Stravix |
| Inspire Medical Systems, INC. | $24.84 | 2023 | Inspire |
| Octapharma USA, INC. | $17.90 | 2025 | Fibryga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Homicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.